Evidence map›Paper›PMID 36207358›Full record

ArticleScientific reports2022

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.

Robbie R Haines, Papanin Putsathit, Katherine A Hammer, Anna S Tai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Robbie R HainesSchool of Biomedical Sciences, The University of Western Australia, 30 Stirling Hwy, Crawley, Perth, WA, 6009, Australia. robbie.haines@uwa.edu.au.
Papanin PutsathitSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Katherine A HammerSchool of Biomedical Sciences, The University of Western Australia, 30 Stirling Hwy, Crawley, Perth, WA, 6009, Australia.
Anna S TaiDepartment of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
University of Western Australia · AUEdith Cowan University · AUSir Charles Gairdner Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistant (MDR) P. aeruginosa accounts for 35% of all P. aeruginosa isolated from respiratory samples of patients with cystic fibrosis (CF). The usefulness of β-lactam antibiotics for treating CF, such as carbapenems and later generation cephalosporins, is limited by the development of antibacterial resistance. A proven treatment approach is the combination of a β-lactam antibiotic with a β-lactamase inhibitor. New β-lactam/β-lactamase inhibitor combinations are available, but data are lacking regarding the susceptibility of MDR CF-associated P. aeruginosa (CFPA) to these new combination therapies. In this study we determined MIC values for three new combinations; imipenem-relebactam (I-R), ceftazidime-avibactam (CZA), and ceftolozane-tazobactam (C/T) against MDR CFPA (n = 20). The MIC

Indexed as

CeftazidimePseudomonas InfectionsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCarbapenemsCephalosporinsDrug CombinationsDrug Resistance, Multiple, BacterialHumansImipenemLactamsMicrobial Sensitivity TestsMonobactamsPiperacillin, Tazobactam Drug CombinationPseudomonas aeruginosaAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCarbapenemsCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDrug CombinationsImipenemLactamsMonobactamsPiperacillin, Tazobactam Drug CombinationrelebactamTazobactam

Identifiers

PMID36207358
PMCPMC9547053
OpenAlexW4303415576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.